Study links acetaminophen to lower prostate cancer risk

May 23, 2011

A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular.

Use of aspirin and other nonsteroidal (NSAIDs), particularly long-term use, has been associated with modestly reduced risk of prostate cancer in some previous . Acetaminophen, a commonly used pain-reliever, is not traditionally considered an NSAID but can have anti-inflammatory effects.

For the current study, researchers led by Eric Jacobs, Ph.D., American Cancer Society , examined the association between acetaminophen use and prostate cancer incidence among 78,485 men in the Cancer Prevention Study II Nutrition Cohort. Information on acetaminophen use was obtained from a questionnaire completed at study enrollment in 1992 and updated using follow-up questionnaires in 1997 and every two years thereafter.

During follow-up from 1992 through 2007, there were 8,092 incident prostate cancer cases identified. Current regular use of acetaminophen (> 30 pills per month) for 5 years or more was associated with lower risk of overall prostate cancer (RR = 0.62, 95% CI 0.44-0.87) as well as lower risk of aggressive prostate cancer (RR = 0.49, 95% CI 0.27-0.88). Current regular use of < 5 years duration was not associated with prostate cancer risk.

"While the results of this observational study suggest that long-term regular acetaminophen use may be associated with lower , our findings require replication by other studies, and do not justify use of acetaminophen to prevent prostate cancer. Acetaminophen is considered relatively safe when used at recommended doses but unintentional acetaminophen overdose is an important cause of ." said Dr. Jacobs. "Still, results of this study could lead to further research on acetaminophen that might provide biological insights about the process of development and how this process could be slowed."

More information: "A Large Cohort Study of Long-term Acetaminophen Use and Prostate Cancer Incidence," Eric J Jacobs, Christina C Newton, Victoria L Stevens, and Susan M Gapstur, Cancer Epidemiol Biomarkers Prev May 17, 2011 cebp.0210.2011; Published OnlineFirst May 17, 2011; doi:10.1158/1055-9965.EPI-11-0210

Related Stories

Recommended for you

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Metabolism can be used to subtype hepatoblastoma tumors

September 18, 2017
Looking at cell metabolism instead of histology, EPFL scientists have identified new biomarkers that could help more accurately classify the two main subtypes of hepatoblastoma, a children liver cancer.

Scientists find bacteria in pancreatic tumors that metabolize a common drug

September 15, 2017
To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic ...

New technologies combined to identify specific DNA defect underlying a type of cancer

September 15, 2017
(Medical Xpress)—A team of researchers from the Netherlands and the U.K. has developed a technique for studying inherited types of cancers using two relatively new technologies—organoid development and CRISPR/Cas9. In ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.